ATE190351T1 - Polypeptide, von endonexin 2 stammend, mit hepatitis b virus rezeptor aktivität und deren verwendungen in diagnotischen und pharmazeutischen zusammensetzungen - Google Patents
Polypeptide, von endonexin 2 stammend, mit hepatitis b virus rezeptor aktivität und deren verwendungen in diagnotischen und pharmazeutischen zusammensetzungenInfo
- Publication number
- ATE190351T1 ATE190351T1 AT93915810T AT93915810T ATE190351T1 AT E190351 T1 ATE190351 T1 AT E190351T1 AT 93915810 T AT93915810 T AT 93915810T AT 93915810 T AT93915810 T AT 93915810T AT E190351 T1 ATE190351 T1 AT E190351T1
- Authority
- AT
- Austria
- Prior art keywords
- endonexin
- hepatitis
- diagnostic
- pharmaceutical compositions
- receptor activity
- Prior art date
Links
- 241000700721 Hepatitis B virus Species 0.000 title 1
- 102000018265 Virus Receptors Human genes 0.000 title 1
- 108010066342 Virus Receptors Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 230000009261 transgenic effect Effects 0.000 abstract 2
- 206010019837 Hepatocellular injury Diseases 0.000 abstract 1
- 101000780122 Homo sapiens Annexin A5 Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4721—Lipocortins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP92401971 | 1992-07-08 | ||
PCT/EP1993/001745 WO1994001554A1 (en) | 1992-07-08 | 1993-07-06 | Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE190351T1 true ATE190351T1 (de) | 2000-03-15 |
Family
ID=8211682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT93915810T ATE190351T1 (de) | 1992-07-08 | 1993-07-06 | Polypeptide, von endonexin 2 stammend, mit hepatitis b virus rezeptor aktivität und deren verwendungen in diagnotischen und pharmazeutischen zusammensetzungen |
Country Status (12)
Country | Link |
---|---|
EP (2) | EP0672136B1 (de) |
JP (2) | JPH07509776A (de) |
AT (1) | ATE190351T1 (de) |
AU (1) | AU676483B2 (de) |
CA (1) | CA2139735A1 (de) |
DE (1) | DE69328035T2 (de) |
DK (1) | DK0672136T3 (de) |
ES (1) | ES2146231T3 (de) |
GR (1) | GR3033482T3 (de) |
PT (1) | PT672136E (de) |
SG (1) | SG46493A1 (de) |
WO (1) | WO1994001554A1 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0741144B1 (de) * | 1994-11-11 | 2002-07-24 | Noboru Kaneko | Monoklonaler antikörper gegen antiannexin-v, verfahren zu seiner herstellung und seiner verwendung |
JP2001508054A (ja) * | 1996-12-30 | 2001-06-19 | イノジェネティックス・ナムローゼ・フェンノートシャップ | HBsAg由来アネキシンV結合ポリペプチドおよびその使用 |
ATE349225T1 (de) * | 1997-11-06 | 2007-01-15 | Innogenetics Nv | Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv |
US6344362B1 (en) | 1998-03-12 | 2002-02-05 | Ministero Dell Universita'e Della Ricerca Scientifica E Tecnologica (M.U.R.S.T. ) | Use of a recombinant protein as receptor of a hepatitis virus |
IT1299581B1 (it) * | 1998-03-12 | 2000-03-16 | Ministero Dell Uni Della Ricer | Uso di una proteina ricombinante come recettore di un virus dell'epatite |
CN1315963A (zh) * | 1998-09-01 | 2001-10-03 | 基因创新有限公司 | 结合膜联蛋白的苯并二氮杂䓬类和苯并硫杂吖庚因衍生物和hbsag肽,其组合物和用途 |
US7635680B2 (en) | 2001-02-21 | 2009-12-22 | Alavita Pharmaceuticals, Inc. | Attenuation of reperfusion injury |
US7645739B2 (en) | 2001-02-21 | 2010-01-12 | Alavita Pharmaceuticals, Inc. | Modified annexin compositions and methods of using same |
DE60219611T2 (de) | 2001-02-21 | 2007-12-27 | Alavita Pharmaceuticals, Inc., Mountain View | Modifizierte annexin-proteine und verhinderung und behandlung von thrombose |
US7635676B2 (en) | 2001-02-21 | 2009-12-22 | Alavita Pharmaccuticals, Inc. | Modified annexin proteins and methods for their use in organ transplantation |
US20060057591A1 (en) * | 2004-09-15 | 2006-03-16 | Canadian Blood Services | Method for preventing viral infection |
ES2494840T3 (es) | 2005-03-15 | 2014-09-16 | Fujirebio Europe N.V. | Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas |
US8383879B2 (en) * | 2009-12-04 | 2013-02-26 | Academia Sinica | Non-human animal disease mode for hepatitis B virus-associated disease |
JP6445447B2 (ja) * | 2012-11-12 | 2018-12-26 | ルプレヒト−カールス−ウニヴェルジテート ハイデルベルクRuprecht−Karls−Universitaet Heidelberg | Hbv及び/又はhdv感受性の細胞、細胞株及び非ヒト動物の開発 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI861417A0 (fi) * | 1985-04-15 | 1986-04-01 | Endotronics Inc | Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav. |
PT87083B (pt) * | 1987-03-28 | 1992-07-31 | Boehringer Ingelheim Int | Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem |
EP0288198A3 (de) * | 1987-04-20 | 1989-03-29 | Takeda Chemical Industries, Ltd. | Peptidherstellung |
US4873316A (en) * | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
DE3737239A1 (de) * | 1987-11-03 | 1989-10-12 | Behringwerke Ag | Gentechnische herstellung von anticoagulatorischem protein pp4 |
EP0339285A3 (de) * | 1988-03-31 | 1989-11-29 | RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) | Rekombinantes Endonexin II |
FR2637184A1 (fr) * | 1988-10-05 | 1990-04-06 | Inst Nat Sante Rech Med | Anticorps monoclonal reconnaissant une region pre-s1 de la grande proteine d'enveloppe du virus de l'hepatite b et ses applications, notamment pour le diagnostic in vitro et le traitement de l'hepatite b |
EP0389983A3 (de) * | 1989-03-31 | 1991-01-16 | Abbott Laboratories | Monoklonale Antikörper gegen PreS2- und PreS1-Polypeptide des Umhüllungsproteins des Hepatite B-Virus |
DE4012341A1 (de) * | 1990-04-18 | 1991-10-24 | Behringwerke Ag | Monoklonale antikoerper gegen pp4, verfahren zu ihrer herstellung und ihre verwendung |
-
1993
- 1993-07-06 DK DK93915810T patent/DK0672136T3/da active
- 1993-07-06 JP JP6502941A patent/JPH07509776A/ja active Pending
- 1993-07-06 AT AT93915810T patent/ATE190351T1/de not_active IP Right Cessation
- 1993-07-06 EP EP93915810A patent/EP0672136B1/de not_active Expired - Lifetime
- 1993-07-06 CA CA002139735A patent/CA2139735A1/en not_active Abandoned
- 1993-07-06 ES ES93915810T patent/ES2146231T3/es not_active Expired - Lifetime
- 1993-07-06 WO PCT/EP1993/001745 patent/WO1994001554A1/en active IP Right Grant
- 1993-07-06 PT PT93915810T patent/PT672136E/pt unknown
- 1993-07-06 EP EP99113609A patent/EP0968648A1/de not_active Withdrawn
- 1993-07-06 SG SG1996005112A patent/SG46493A1/en unknown
- 1993-07-06 DE DE69328035T patent/DE69328035T2/de not_active Expired - Fee Related
- 1993-07-06 AU AU45646/93A patent/AU676483B2/en not_active Ceased
-
2000
- 2000-05-24 GR GR20000401179T patent/GR3033482T3/el not_active IP Right Cessation
-
2002
- 2002-07-29 JP JP2002219651A patent/JP2003189759A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
DK0672136T3 (da) | 2000-08-21 |
DE69328035D1 (de) | 2000-04-13 |
JPH07509776A (ja) | 1995-10-26 |
CA2139735A1 (en) | 1994-01-20 |
EP0672136A1 (de) | 1995-09-20 |
GR3033482T3 (en) | 2000-09-29 |
WO1994001554A1 (en) | 1994-01-20 |
ES2146231T3 (es) | 2000-08-01 |
DE69328035T2 (de) | 2000-11-02 |
EP0672136B1 (de) | 2000-03-08 |
AU676483B2 (en) | 1997-03-13 |
AU4564693A (en) | 1994-01-31 |
EP0968648A1 (de) | 2000-01-05 |
JP2003189759A (ja) | 2003-07-08 |
PT672136E (pt) | 2000-08-31 |
SG46493A1 (en) | 1998-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE190351T1 (de) | Polypeptide, von endonexin 2 stammend, mit hepatitis b virus rezeptor aktivität und deren verwendungen in diagnotischen und pharmazeutischen zusammensetzungen | |
PT725824E (pt) | Epitopos de celulas t humanas imunodominantes do virus da hepatite c | |
ATE216225T1 (de) | Diagnostische verfahren und pharmazeutische zusammensetzungen auf der basis von notch- proteinen und nukleinsäuren | |
ATE102956T1 (de) | Polypeptide und deren derivate und deren verwendung in pharmazeutischen und diagnostischen zusammensetzungen. | |
LV10507A (lv) | Vektors sunas eritroproteins farmaceitiska kompozicija | |
DK0792287T3 (da) | Peptidanaloger af humant basisk myelinprotein | |
ATE140969T1 (de) | Il-3 mit zusätzlichen cysteinresten und chemische modifikationen davon | |
DE69230993D1 (de) | Rekombinante viren vektoren zur expression in muskelzellen | |
ATE189684T1 (de) | Rekombinante polypeptide und peptide, dafür kodierende nukleinsäuren und ihre verwendung in der tuberkulose-diagnose | |
ATE199377T1 (de) | Protein mit cytokinaktivität, rekombinant-dns, expressionsvektor und wirtszellen zu seiner herstellung | |
BR9306272A (pt) | Peptídeo e composiçao farmacêutica | |
EA200000685A1 (ru) | Комплекс ifnar2/ifn | |
LV11816A (lv) | Implantejama zalu forma | |
ATE67783T1 (de) | Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen. | |
ES2080060T3 (es) | Proteinas que tienen actividad de union a interferon-gamma. | |
AU3902489A (en) | Non-glycosylated, recombinant human IL2 in the reduced form, the process for obtaining it and its use as a medicament | |
ATE136933T1 (de) | Rekombinante hbsag hybridpartikel, die morphologische eigenschaften von hbsag-antigen haben und eine immunogene sequenz enthalten, die neutralisierende antikörper gegen hiv induziert oder die von diesen antikörpern erkannt ist, nukleotide sequenzen, die diese partikel codieren und sie enthaltende impfstoffe | |
KR910700259A (ko) | T-세포 인지성 펩티드 변형에 의해 면역반응에 영향을 주는 방법 | |
FR2655855B1 (fr) | Protection genetique d'animaux contre l'infection par le virus leucemogene bovin, et provirus et virus recombinant derive de ce virus. | |
MX9604539A (es) | Aminoacidos modificados para la distribucion de farmaco. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |